Citations

Showing 10 of 108094 citations.

The breadth of the diaphragm: updates in embryogenesis and role of imaging
Koo, Chi Wan , Johnson, Tucker F. , Gierada, David S. , White, Darin , Matsumoto, Jane M., Levin, David L. , White, Darin B, Blackmon, Shanda, Choe, Jooae, Allen, Mark S. , Kuzo, Ronald S. , Blackmon, Shanda , Choe, Jooae

Mayo Clinic

The British Journal of Radiology | February 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: 20170600

10.1259/bjr.20170600 | PMID 29485899 Get It

Prevention of liver cancer with new curative hepatitis C antivirals: Real‐world challenges
Soriano, Vincent , Tefferi, Ayalew , Soriano, Vicente

Mayo Clinic

Cancer | February 27, 2018 | Volume: 124 | Issue: 8 | Pages: 1647-1649

10.1002/cncr.31291 | PMID 29486060 Get It

New antiviral therapies cure most patients with hepatitis C and prevent the development of cirrhosis and hepatocellular carcinoma. The major challenges for global hepatitis C virus eradication are the identification of patients with chronic hepatitis C, referrals to treatment, and elevated drug prices. See also pages 1644‐46.
Faculty Opinions recommendation of Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Huebert, Robert C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732110855.793542979 Get It

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival
Lassak, Adam, Dean, Mathew, Wilk, Anna , Marrero, Luis , Trillo-Tinoco, Jimena , Boulares, A. Hamid , Valle, Luis Del , Reiss, Krzysztof , Wyczechowska, Dorota Danuta , Sarkaria, Jann N. , Peruzzi, Francesca , Ochoa, Augusto C.

Mayo Clinic

Molecular and Cellular Biology | February 27, 2018 | Volume: 38 | Issue: 10 | Pages: No page available

10.1128/mcb.00608-17 | PMID 29483302 Get It

Expression of Embryonic Lethal Abnormal Vision (ELAV)-Like Protein HuR and Cyclooxygenase-2 (COX-2) in Ewing Sarcoma
Do, Sung‐Im , Araujo, Eduard Santini, Kalil, Ricardo K. , Bacchini, Patrizia, Bertoni, Franco, Unni, K. Krishnan, Park, Yong-Koo , Araujo, Eduardo Santini

Mayo Clinic

Tumori Journal | February 27, 2018 | Volume: 94 | Issue: 3 | Pages: 347-350

10.1177/030089160809400310 | PMID 18705402 Get It

Aims and Background HuR is a member of the family of ELAV (embryonic lethal abnormal vision)-like proteins that stabilize several cellular mRNAs by binding to AU-rich elements in the 3’ untranslated region of the mRNA. Cyclooxygenase-2 (COX-2) is a well known enzyme that promotes tumor growth and metastasis. Recent studies have shown that HuR can stabilize the mRNA of COX-2, and cytoplasmic expression of HuR is associated with increased COX-2 expression in some cancers. The aim of this study was to investigate the correlation between COX-2 and HuR in Ewing sarcoma. Methods The expression patterns for HuR and COX-2 were assessed via immunochemical analysis of 70 Ewing sarcoma samples. Results Nuclear HuR expression was observed in 12 of 70 (17.1%) cases, but cytoplasmic expression was not observed. COX-2 expression was seen in 25 of 70 (35.7%) samples. Nuclear HuR and COX-2 were simultaneously expressed in 8 of 70 (11.4%) samples. The expression of nuclear HuR was significantly associated with COX-2 expression (P = 0.014). Neither HuR nor COX-2 expression showed a correlation with age or sex. Conclusions COX-2 expression in Ewing sarcoma may not be directly related to mRNA stabilization by HuR. However, a correlation between COX-2 expression and nuclear HuR expression through indirect mRNA stabilization can be suggested.
Considering the cost of a simultaneous versus staged approach to resection of colorectal cancer with synchronous liver metastases in a publicly funded healthcare model
Souder, Emily , Azin, Arash , Hirpara, Dhruvin H. , Walker, Richard , Quereshy, Fayez A. , Le Souder, Emily B , Cleary, Sean, Quereshy, Fayez , Cleary, Sean P.

Mayo Clinic

Journal of Surgical Oncology | February 27, 2018 | Volume: 117 | Issue: 7 | Pages: 1376-1385

10.1002/jso.25020 | PMID 29484664 Get It

BackgroundSimultaneous resection for colorectal cancer with synchronous liver metastases is an established alternative to a staged approach. This study aimed to compare these approaches with regards to economic parameters and short‐term outcomes.MethodsA retrospective cohort analysis was conducted between 2005 and 2016. The primary outcome was cost per episode of care. Secondary measures included 30‐day clinical outcomes. A multivariate analysis was performed to determine the adjusted effect of a simultaneous surgical approach on total cost of care.ResultsFifty‐three cases were identified; 27 in the staged approach, and 26 in the simultaneous group. Age (P = 0.49), sex (P = 0.20), BMI (P = 0.74), and ASA class (P = 0.44) were comparable between groups. Total cost ($20297 vs $27522), OR ($6830 vs $10376), PACU ($675 vs $1182), ward ($7586 vs $11603) and pharmacy costs ($728 vs $1075) were significantly less for the simultaneous group (P < 0.05). The adjusted rate ratio for total cost of care in the staged group compared to simultaneous group was 1.51 (95%CI: 1.16‐1.97, P < 0.05). The groups had comparable Clavien‐Dindo scores (P = 0.89), 30‐day readmissions (P = 0.44), morbidity (P = 0.50) and mortality (P = 1.00).ConclusionsOur study demonstrates that a simultaneous approach is associated with a significantly lower total cost while maintaining comparable short‐term outcomes.
Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance
Federer‐Gsponer, Joël R. , Quintavalle, Cristina , Müller, David C. , Dietsche, Tanja, Perrina, Valeria, Lorber, Thomas , Juškevičius, Darius , Lenkiewicz, E., Zellweger, Tobias, Barrett, Michael T. , Rentsch, Cyrill A. , Bubendorf, Lukas , Lenkiewicz, Elisabeth, Gasser, Thomas , Ruiz, Christian Felipe , Bubendorf, Lukas

Mayo Clinic

The Journal of Pathology | February 27, 2018 | Volume: 245 | Issue: 1 | Pages: 74-84

10.1002/path.5052 | PMID 29484655 Get It

AbstractUnderstanding the evolutionary mechanisms and genomic events leading to castration‐resistant (CR) prostate cancer (PC) is key to improve the outcome of this otherwise deadly disease. Here, we delineated the tumour history of seven patients progressing to castration resistance by analysing matched prostate cancer tissues before and after castration. We performed genomic profiling of DNA content‐based flow‐sorted populations in order to define the different evolutionary patterns. In one patient, we discovered that a catastrophic genomic event, known as chromothripsis, resulted in multiple CRPC tumour populations with distinct, potentially advantageous copy number aberrations, including an amplification of FK506 binding protein 4 (FKBP4, also known as FKBP52), a protein enhancing the transcriptional activity of androgen receptor signalling. Analysis of FKBP4 protein expression in more than 500 prostate cancer samples revealed increased expression in CRPC in comparison to hormone‐naïve (HN) PC. Moreover, elevated FKBP4 expression was associated with poor survival of patients with HNPC. We propose FKBP4 amplification and overexpression as a selective advantage in the process of tumour evolution and as a potential mechanism associated with the development of CRPC. Furthermore, FKBP4 interaction with androgen receptor may provide a potential therapeutic target in PC. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.
Catherine, Tangen, Lucia, M. Scott , Bivalacqua, Trinity J. , Kassouf, Wassim , Bangs, Richard Carlton, Plets, Melissa , Black, Peter C. , Lerner, Seth P. , McConkey, David James , Woods, Michael E. , Thompson, Ian M. , Singh, Parminder Pal

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS527-TPS527

10.1200/jco.2018.36.6_suppl.tps527 Get It

TPS527 Background: Radical cystectomy is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC). Based on the reported efficacy of atezolizumab in metastatic urothelial carcinoma and the known expression of PD-L1 expression in NMIBC after BCG therapy, this trial will evaluate the activity of atezolizumab in BCG-unresponsive high risk NMIBC. Methods: This is a single arm phase II trial testing systemic atezolizumab (1200 mg IV) every 3 weeks for one year in 135 patients with BCG-unresponsive high risk NMIBC. The study will enroll 70 patients with CIS (with or without concomitant Ta/T1) and 65 with Ta/T1 only. Patients with CIS at baseline will undergo mandatory repeat biopsy at 6 months, and all other patients only for suspected recurrence. Patients with persistent CIS, high grade Ta/T1 recurrence or progression to muscle invasive or metastatic disease will be taken off treatment. The co-primary endpoints are: (1) complete response (CR) at 6 months in the CIS subgroup, and (2) event-free survival (EFS) at 18 months in the overall population. A hierarchical approach will be used to test the two co-primary endpoints. Secondary endpoints include duration of CR as well as progression-free, cystectomy-free, bladder cancer-specific, and overall survival in all patients. Response will be correlated to expression of PD-L1 and CD8 by IHC, and to molecular subtypes and immune signatures by RNA-sequencing. If ≥28 (40%) CIS patients respond, the agent will be considered promising. This design has a significance level of 4.6%, and a power of 96%. If the lower bound of the 90% confidence interval of the 18-month EFS excludes 20%, the investigators will conclude the regimen significantly improves EFS relative to historical data (type I error rate 0.05 and statistical power 0.93). Successful completion of this trial could lead to a new treatment paradigm for patients with BCG-unresponsive high risk NMIBC. Funding: NIH/NCI grants: CA180888, CA180819, CA180820, CA180821, and CA180863. Clinical trial registry: NCT02844816 Clinical trial information: NCT02844816.
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficien
Ryan, Charles J. , Abida, Wassim , Dumbadze, Igor, Given, Robert , Petrylak, Daniel P. , Redfern, Charles H., Scher, Howard I. , Watkins, Simon P. , Simmons, Andrew D. , Passler, Luke, Golsorkhi, Tony, Chowdhury, Simon, Watkins, Simon P , Bryce, Alan H. , Balar, Arjun Vasant , Morris, David S. , Passler, Luke

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS389-TPS389

10.1200/jco.2018.36.6_suppl.tps389 Get It

TPS389 Background: Recent data have shown that up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM, or another homologous recombination DNA repair gene. Such mutations can be used as a molecular marker to select patients for targeted treatment with poly(ADP-ribose) polymerase inhibitors (PARPis), which are lethal to cells with HRD. Treatment with PARPis has shown preliminary evidence of antitumor activity in patients with mCRPC and a mutation in a homologous recombination DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent inhibitor of PARP1, PARP2, and PARP3, in patients with mCRPC associated with HRD. Methods: TRITON3 (NCT02975934) is a randomized, phase 3 study evaluating rucaparib 600 mg BID vs physician’s choice of abiraterone, enzalutamide, or docetaxel in patients with mCRPC and a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation (identified by prior local testing or central testing during screening). Patients must have progressed on androgen receptor signaling–directed therapy in the mCRPC setting; prior PARPi treatment or chemotherapy for mCRPC are exclusion criteria. Patients will be randomly assigned in a 2:1 ratio to either rucaparib or physician’s choice, with the possibility for cross over from the comparator treatment to rucaparib upon radiographic progression confirmed by independent radiology review. The primary endpoint is radiographic progression-free survival (modified RECIST v1.1/PCWG3 criteria) assessed by independent radiology review. Secondary endpoints include objective response rate, duration of response, patient-reported outcomes, overall survival, and safety. Pretreatment blood samples collected from all patients will enable development of a noninvasive plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈400) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02975934.
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida, Wassim , Chatta, Gurkamal , Dawson, Nancy A. , Guancial, Elizabeth A. , Hussain, Arif , Jha, Gautam , Lipsitz, David, Petrylak, Daniel P. , Ryan, Charles J. , Stanton, T., Zhang, Jingsong , Simmons, Andrew D. , Go, Jowell, Golsorkhi, Tony, Chowdhury, Simon, Scher, Howard I. , Bryce, Alan H. , Balar, Arjun Vasant , Patnaik, Akash , Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS388-TPS388

10.1200/jco.2018.36.6_suppl.tps388 Get It

TPS388 Background: Up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM or another homologous recombination (HR) DNA repair gene that can serve as a molecular marker to select those who may respond to poly(ADP-ribose) polymerase inhibitors (PARPis). PARPis are lethal to cells with HRD, and PARPi treatment has shown preliminary evidence of an antitumor effect in patients with mCRPC who harbor a mutation in an HR DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with HRD. Methods: TRITON2 (NCT02952534) is a phase 2 study evaluating rucaparib 600 mg BID in patients with mCRPC. Patients with a deleterious germline or somatic BRCA1, BRCA2 or ATM mutation (per prior local test or central test during screening) will be enrolled into 1 of 2 cohorts based on the presence or absence of measurable visceral and/or nodal disease. An exploratory cohort will enroll patients with an alteration in any of 12 other prespecified HR genes (eg, RAD51C, RAD51D and PALB2), with or without measurable visceral and/or nodal disease. Patients must have progressed on androgen receptor signaling–directed therapy and 1 prior taxane-based chemotherapy for mCRPC. Patients who received prior treatment with a PARPi, mitoxantrone, cyclophosphamide or platinum-based chemotherapy are excluded. The primary endpoint is objective response rate measured using modified RECIST v1.1/PCWG3 for patients with soft-tissue disease and prostate-specific antigen response for patients with nonmeasurable disease. Secondary endpoints include duration of response, radiographic progression-free survival, overall survival, clinical benefit rate and safety. Pretreatment blood samples collected from all patients will enable development of a plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈160) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02952534.